JAK inhibitors
Drug Safety Update
April 2023: Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality
October 2021: Tofacitinib (Xeljanz▼): new measures to minimise risk of major adverse cardiovascular events and malignancies
August 2020: Baricitinib (Olumiant▼): increased risk of diverticulitis, particularly in patients with risk factors
March 2020: Baricitinib (Olumiant▼): risk of venous thromboembolism
March 2020: Tofacitinib (Xeljanz▼): new measures to minimise risk of venous thromboembolism and of serious and fatal infections
NICE Guidance (See also drug specific guidance below)
NG100: Rheumatoid arthritis in adults: management, July 2018 (updated October 2020)
Local Guidance
See here for local IBD HCD (Adults) pathway, for use of JAK inhibitors in IBD
| Pack |
|---|
| 28 tablet (4 x 7 tablets) |
| Pack |
|---|
| 28 tablet (4 x 7 tablets) |
- On Formulary Preferred
- On Formulary Second Line
- On Formulary Third Line
- Specialist Initiation
- Secondary Care Only
- Not Approved for Formulary